Publications by authors named "Linus Angenendt"

Claim this Profile
E
Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
Eloísa Felipe Fumero, Carolin Walter, Joris Maximillian Frenz, Franca Seifert, Vijay Alla, Linus Angenendt

Blood· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.
Inna Shaforostova, Simon Call, Georg Evers, Christian Reicherts, Linus Angenendt

EJHaem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears.
Jacqueline Kockwelp, Sebastian Thiele, Jannis Bartsch, Lars Haalck, Jörg Gromoll, Linus Angenendt

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).
Alexander Pohlmann, Eva Bentgens, Christoph Schülke, David Kuron, Christian Reicherts, Linus Angenendt

Ann Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia.
Sergi Beneyto-Calabuig, Anne Kathrin Merbach, Jonas-Alexander Kniffka, Magdalena Antes, Chelsea Szu-Tu, Linus Angenendt

Cell Stem Cell· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.
David Kuron, Alexander Pohlmann, Linus Angenendt, Torsten Kessler, Rolf Mesters

Ann Hematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.
Linus Angenendt, Christoph Röllig, Pau Montesinos, Farhad Ravandi, Gunnar Juliusson

Blood· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Andrew F Berdel, Raphael Koch, Joachim Gerss, Marcus Hentrich, Rudolf Peceny, Linus Angenendt

Ann Hematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging antibody-based therapies for the treatment of acute myeloid leukemia.
Linus Angenendt, Jan-Henrik Mikesch, Christoph Schliemann

Cancer Treat Rev· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Andrew F Berdel, Leo Ruhnke, Linus Angenendt, Martin Wermke, Christoph Röllig

Blood Adv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia.
Daniela V Wenge, Klaus Wethmar, Corinna A Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt

Cancers (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML.
Linus Angenendt, Marius Wöste, Jan-Henrik Mikesch, Maria Francisca Arteaga, Adrian Angenendt

Blood Adv· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Linus Angenendt, Isabel Hilgefort, Jan-Henrik Mikesch, Bernhard Schlüter, Wolfgang E Berdel

Ann Hematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Linus Angenendt

Blood· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.
Christoph Schliemann, Teresa Hemmerle, Andrew F Berdel, Linus Angenendt, Andrea Kerkhoff

Eur J Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
Christoph Schliemann, Torsten Kessler, Andrew F Berdel, Teresa Hemmerle, Linus Angenendt

Br J Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
Matthias Floeth, Sandra Elges, Joachim Gerss, Christian Schwöppe, Torsten Kessler, Linus Angenendt

Br J Haematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
Clément Larrue, Nathan Guiraud, Pierre-Luc Mouchel, Marine Dubois, Thomas Farge, Linus Angenendt

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder.
Sheila K Pierson, Johnson S Khor, Jasira Ziglar, Amy Liu, Katherine Floess, Linus Angenendt

Cell Rep Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.
Klaus Wethmar, Svenja Matern, Eva Eßeling, Linus Angenendt, Heike Pfeifer

Bone Marrow Transplant· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
Christoph Schliemann, Mirjam Gerwing, Hauke Heinzow, Saliha Harrach, Christian Schwöppe, Linus Angenendt

Cancers (Basel)· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.
Leoni Rolfes, Steffen Pfeuffer, Tobias Ruck, Susanne Windhagen, Ilske Oschlies, Linus Angenendt

Neurol Neuroimmunol Neuroinflamm· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
Linus Angenendt, Eike Bormann, Caroline Pabst, Vijay Alla, Dennis Görlich, Adrian Angenendt

Leukemia· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromosomal Abnormalities and Prognosis in -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.
Linus Angenendt, Christoph Röllig, Pau Montesinos, David Martínez-Cuadrón, Eva Barragan

J Clin Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M Knecht, Olga Buzovetsky, Linus Angenendt

Nat Commun· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis